BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 03, 2003
 |  BioCentury  |  Strategy

Small is beautiful

Pharma companies are always looking to expand sales of their drugs, either through increased marketing or expanded indications. But for large companies, the work required to get a label for a rare disease may not be worth the incremental sales. Aspreva Pharmaceuticals Corp. believes it can make money by doing this for phama partners, while at the same time giving its own investors a low-risk, late-stage play.

Last month, Aspreva entered into its first deal, receiving exclusive worldwide rights outside of Japan to develop Roche's CellCept mycophenolate mofetil for autoimmune diseases. Roche (SWX:ROCZ,...

Read the full 460 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >